학술논문
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Document Type
Article
Author
Sands, Bruce E; Irving, Peter M; Hoops, Timothy; Izanec, James L; Gao, Long-Long; Gasink, Christopher; Greenspan, Andrew; Allez, Matthieu; Danese, Silvio; Hanauer, Stephen B; Jairath, Vipul; Kuehbacher, Tanja; Lewis, James D; Loftus, Edward V; Mihaly, Emese; Panaccione, Remo; Scherl, Ellen; Shchukina, Oksana B; Sandborn, William J; Afzali, Anita; Aitova, Lilia; Aldeguer i Mante, Xavier; Allez, Matthieu; Altorjay, István; Argüelles Arias, Federico; Armuzzi, Alessandro; Augustyn, Monika; Bafutto, Mauro; Barrio, Jesus; Begun, Jakob; Behrend, Clint; Bezemer, Geert; Bonnaud, Guillaume; Brankovic, Marija; Byung, Ik Jang; Calvet Calvo, Xavier; Chachu, Karen; Chebli, Julio Maria Fonseca; Cheon, Jae Hee; Cichoz-Lach, Halina; Clark, Larry; Cummings, Fraser; Dalal, Kunal; Danese, Silvio; De Boer, Nanne; De Lourdes Ferrari, Maria; Désilets, Etienne; Dugalic, Predrag; Duvall, George; Fedorishina, Olga; Filip, Rafal; Flores, Cristina; Fogel, Ronald; Fon, James; Frankel, Michael; Friedenberg, Keith; Fries, Walter; Galina, Vassileva; Gietka, Piotr; Goel, Rishi; Hasselblatt, Peter; Herfarth, Hans; Herszényi, László; Hindryckx, Pieter; Hoentjen, Frank; Horjus Talabur Horje, Carmen; Iduru, Satish; Irving, Peter; Isfort, Robert; Jairath, Vipul; Jones, Michael; Kalimullina, Dilara; Katz, Jeffry; Kaur, Manreet; Khurana, Sunil K; Kim, Joo Sung; Kim, Youngho; Kleczkowski, Dariusz; Knezevic, Slavko; Knoll, Aaron; Korman, Louis Y; Kotzev, Iskren; Kulyapin, Andrey; Lee, Kang Moon; Leemreis, Desiree; Leszczyszyn, Jaroslaw; Limdi, Jimmy; Lissauer, Jack; Loftus, Edward; Malecka-Panas, Ewa; Marshall, John; Mihály, Emese; Milan, Lukas; Monteleone, Giovanni; Nagorni, Aleksandar; Owczarek, Danuta; Palekar, Nichole; Panaccione, Remo; Park, Young Soo; Park, Sang Hyoung; Parra, Rogério; Patai, Árpád; Patel, Kamal; Patel, Bhaktasharan; Pershko, Anatoly; Petrova, Elina; Pineton de Chambrun, Guillaume; Randall, Charles; Riestra Menendez, Sabino; Ritter, Timothy; Rivero, Montserrat; Roblin, Xavier; Rocca, Rodolfo; Romatowski, Jacek; Rydzewska, Grazyna; Saibeni, Simone; Salzberg, Bruce; Sarles, Harry; Saunders, John; Savarino, Edoardo Vincenzo; Serclova, Zuzana; Shchukina, Oksana; Siegel, Jonathan; Soofi, Najm; Sparrow, Miles; Stokesberry, David; Suiter, Daniel; Svorcan, Petar; Tkachev, Alexander; Tsonev, Nikolay; Tünde, Kristóf; Ulbrych, Jan; Vanasek, Tomas; Varga, Márta; Vermeire, Severine; Vicente Lidon, Raquel; Weiss, Michael L; Wesley, Emma; Winstead, Nathaniel; Wojcik, Katarzyna; Wypych, Joanna; Zaltman, Cyrla; Zdena, Zadorova
Source
The Lancet; June 2022, Vol. 399 Issue: 10342 p2200-2211, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.